We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tenet Healthcare Corporation (THC - Free Report) delivered third-quarter 2019 adjusted net income of 58 cents per share, beating the Zacks Consensus Estimate by 107.1% on the back of volume growth and better revenues. Moreover, the bottom line shot up 100% year over year.
Quarterly Operational Update
Net operating revenues came in at $4.5 billion, up 1.8% year over year. Additionally, the top line beat the Zacks Consensus Estimate by 2.4% on contributions from the Hospital & Other and Ambulatory segments.
Hospital segment’s same-hospital admissions were up 3.6% year over year.
Quarterly Segment Details
Hospital & Other
Net operating revenues in the Hospital Operations and Other segment totaled $3.8 billion, up 2.3% year over year. This upside is mainly attributable to revenue growth on same-hospital basis. However, the same was partly offset by hospital divestitures.
On same-hospital basis, patient revenues were $3.56 billion, up 5.8% year over year.
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $343 million, up 7.1% year over year.
Ambulatory Segment
The Ambulatory segment generated net operating revenues of $522 million, up 4% year over year.
Additionally, the segment reported adjusted EBITDA of $207 million, up 13.7% year over year.
Conifer Segment
Conifer’s revenues decreased 9.4% from the prior-year quarter’s level to $336 million. This was mainly due to the company’s client attrition following certain divestitures.
The segment’s adjusted EBITDA of $90 million was up 11.1% year over year.
Tenet Healthcare Corporation Price, Consensus and EPS Surprise
As of Sep 30, 2019, Tenet Healthcare had cash and cash equivalents of $314 million, down 23.6% from the number at 2018 end.
The company exited the third quarter with $14.8 billion of long-term debt, up 1.5% from the 2018-end level.
Net cash provided by operating activities for the first nine months of 2019 was $713 million, down 10.8% year over year.
2019 Outlook
Post third-quarter results, the company revised its guidance. Revenues are now expected between $18.350 billion and $18.550 billion compared with the earlier view of $18-$18.4 billion.
Adjusted earnings per share are now projected between $2.25 and $2.91. Adjusted EBITDA is estimated between $2.650 billion and $2.750 billion. Tenet Healthcare anticipates adjusted free cash flow of $600-$800 million. While net cash provided by operating activities is predicted between $1.045 billion and $1.325 billion.
Q419 Guidance
Following third-quarter results, the company provided an outlook for the fourth quarter.
Tenet Healthcare now anticipates revenues in the range of $4.678-$4.878 billion for the current quarter.
The company forecasts adjusted EBITDA between $749 million and $849 million.
Adjusted earnings per share from continuing operations are likely to vary between 57 cents and $1.23.
Among other players from the medical sector, having already reported third-quarter earnings, the bottom-line results of UnitedHealth Group Incorporated (UNH - Free Report) , Anthem Inc. and Centene Corporation (CNC - Free Report) topped the respective Zacks Consensus Estimate.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tenet Healthcare (THC) Q3 Earnings & Revenues Beat Estimates
Tenet Healthcare Corporation (THC - Free Report) delivered third-quarter 2019 adjusted net income of 58 cents per share, beating the Zacks Consensus Estimate by 107.1% on the back of volume growth and better revenues. Moreover, the bottom line shot up 100% year over year.
Quarterly Operational Update
Net operating revenues came in at $4.5 billion, up 1.8% year over year. Additionally, the top line beat the Zacks Consensus Estimate by 2.4% on contributions from the Hospital & Other and Ambulatory segments.
Hospital segment’s same-hospital admissions were up 3.6% year over year.
Quarterly Segment Details
Hospital & Other
Net operating revenues in the Hospital Operations and Other segment totaled $3.8 billion, up 2.3% year over year. This upside is mainly attributable to revenue growth on same-hospital basis. However, the same was partly offset by hospital divestitures.
On same-hospital basis, patient revenues were $3.56 billion, up 5.8% year over year.
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $343 million, up 7.1% year over year.
Ambulatory Segment
The Ambulatory segment generated net operating revenues of $522 million, up 4% year over year.
Additionally, the segment reported adjusted EBITDA of $207 million, up 13.7% year over year.
Conifer Segment
Conifer’s revenues decreased 9.4% from the prior-year quarter’s level to $336 million. This was mainly due to the company’s client attrition following certain divestitures.
The segment’s adjusted EBITDA of $90 million was up 11.1% year over year.
Tenet Healthcare Corporation Price, Consensus and EPS Surprise
Tenet Healthcare Corporation price-consensus-eps-surprise-chart | Tenet Healthcare Corporation Quote
Financial Position
As of Sep 30, 2019, Tenet Healthcare had cash and cash equivalents of $314 million, down 23.6% from the number at 2018 end.
The company exited the third quarter with $14.8 billion of long-term debt, up 1.5% from the 2018-end level.
Net cash provided by operating activities for the first nine months of 2019 was $713 million, down 10.8% year over year.
2019 Outlook
Post third-quarter results, the company revised its guidance. Revenues are now expected between $18.350 billion and $18.550 billion compared with the earlier view of $18-$18.4 billion.
Adjusted earnings per share are now projected between $2.25 and $2.91.
Adjusted EBITDA is estimated between $2.650 billion and $2.750 billion.
Tenet Healthcare anticipates adjusted free cash flow of $600-$800 million. While net cash provided by operating activities is predicted between $1.045 billion and $1.325 billion.
Q419 Guidance
Following third-quarter results, the company provided an outlook for the fourth quarter.
Tenet Healthcare now anticipates revenues in the range of $4.678-$4.878 billion for the current quarter.
The company forecasts adjusted EBITDA between $749 million and $849 million.
Adjusted earnings per share from continuing operations are likely to vary between 57 cents and $1.23.
Zacks Rank and Performance of Other Players
Tenet Healthcare sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Among other players from the medical sector, having already reported third-quarter earnings, the bottom-line results of UnitedHealth Group Incorporated (UNH - Free Report) , Anthem Inc. and Centene Corporation (CNC - Free Report) topped the respective Zacks Consensus Estimate.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>